What is Athelas?
Athelas is a pioneering health-technology company dedicated to enhancing patient outcomes through sophisticated remote monitoring solutions. By enabling healthcare providers to track critical vitals—such as blood glucose, blood pressure, and weight—outside of traditional clinical settings, Athelas effectively bridges the gap between episodic care and continuous health management. This model not only improves patient engagement but also serves as a vital tool for reducing hospital readmission rates and optimizing healthcare delivery. As the industry shifts toward value-based care, Athelas remains at the forefront, providing the infrastructure necessary for providers to maintain high-touch patient relationships in a digital-first environment.
How much funding has Athelas raised?
Athelas has raised a total of $135.5M across 2 funding rounds:
Other Financing Round
$3.5M
Unspecified
$132M
Other Financing Round (2017): $3.5M with participation from Fifty Years, Steamboat Ventures, Initialized Capital, and Liquid2 Ventures
Unspecified (2022): $132M led by Y Combinator, GREENOAKS, Human Capital, Sequoia Capital, Initialized Capital, Tribe Capital Growth Corp I, and General Catalyst
Key Investors in Athelas
Sequoia Capital
A globally renowned venture capital firm with an unparalleled track record of partnering with entrepreneurs to create market-leading companies across the technology and healthcare sectors.
General Catalyst
A venture capital firm focused on identifying transformational business opportunities, providing both strategic capital and operational expertise to help companies scale at inflection points.
Initialized Capital
A dedicated venture firm supporting seed-stage founders across diverse sectors, including health-tech and enterprise SaaS, with a focus on long-term guidance and innovation.
What's next for Athelas?
With the infusion of $132M, Athelas is well-positioned to scale its operational footprint and deepen its integration within the broader healthcare ecosystem. The company's strategic roadmap likely involves expanding its diagnostic capabilities and enhancing its data analytics platform to provide more actionable insights for clinicians. By leveraging its robust capital base, Athelas is expected to pursue aggressive market penetration, potentially exploring new therapeutic areas and strengthening its enterprise partnerships. As the company matures, the focus will shift toward long-term sustainability and the refinement of its proprietary technology to meet the evolving demands of global healthcare systems, ensuring that its remote monitoring solutions remain the gold standard for patient-centric care.
See full Athelas company page
